Chemotherapy of esophageal carcinoma

Onkologie

Volumn 22, Issue 2, 1999, Pages 98-104

  Stahl, Michael ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Adenocarcinoma; Chemotherapy; Esophageal carcinoma; Squamous cell carcinoma

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; FLOXURIDINE; NAVELBINE; PACLITAXEL; VINDESINE;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; HUMAN; LEUKOPENIA; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; REVIEW; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

EID: 0032926933     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026928     Document Type: Review

References (57)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics 1998. CA Cancer J Clin 1998;48:6-29.
2. Zhang ZF, Kurtz R, Marshall JR: Cigarette smoking and esophageal and gastric cardia adenocarcinoma. J Natl Cancer Inst 1997;89:1247-1249.
3. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB, Rotterdam H, Niwa S, Fraumeni JF: Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90: 150-155.
4. Blot WJ: Esophageal cancer trends and risk factors. Semin Oncol 1994;21:403-410.
5. Daly JM, Karnell LH, Menck HR: National cancer data base report on esophageal carcinoma. Cancer 1996;78:1820-1828.
6. Davis S, Shanmugathasa M, Kessler W: Cis-dichlorodiammineplatinum(II) in the treatment of esophageal carcinoma. Cancer Treat Rep 1980;64:709-711.
7. Nasca S, Coninx P, Segal S, Brossel R, Boulenger E, Cattan A: Phase II study of cis-dichlorodiammine-platinum(II) in oesophageal squamous cell carcinoma. Cancer Immunol Immunother 1980;9:36.
8. Engstrom PF, Lavin PT, Klaassen DJ: Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 1983;67: 713-715.
9. Panettiere FJ, Leichman LP, Tilchen EJ, Chen TT: Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: Final report on a Southwest Oncology Group Study. Cancer Treat Rep 1984;68:1023-1024.
10. Ravry MJR, Moore MR, Omura GA, Esseese I, Barlolucci A: Phase II evaluation of cisplatin in squamous carcinoma of the esophagus. A Southeastern Cancer Study Group Trial. Cancer Treat Rep 1985;69:1457-1458.
11. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Colette L, Sahmoud T: Randomised phase II study of cisplatin and 5-fluorouracil versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-1220.
12. Schmoll HJ, Köhne CH, Papageorgiou E, Luft S, Harstrick A, Bachmann P, Hilgard P, Schubert U: Single agent lobaplatin is active in patients with oesophageal squamous cell carcinoma: A pase II evaluation. Proc ASCO 1995;14:201.
13. Bezwoda WR, Derman DP, Weaving A, Nissenbaum M: Treatment of esophageal cancer with vindesine: An open trial. Cancer Treat Rep 1984;68: 783-785.
14. Kolaric K, Maricic Z, Dujmovic I, Roth A: Therapy of advanced esophageal cancer with bleomycin, irradiation and combination of bleomycin and irradiation. Tumori 1976;62:255-262.
15. Harstrick A, Bokemeyer C, Preusser P, KöhneWömpner CH, Meyer HJ, Stahl M, Knipp H, Schmoll HJ, Wilke H: Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol 1992;29:321-322.
16. Ajam JA, Ilson DH, Daugherty K, Kelsen DP: Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol 1995;22(suppl 6):35-40.
17. Conroy T, Etienne PL, Adenis A, Wagener DJT, Paillot B, François E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado FM, Merle S, Wils J: Phase II trial of vinorelbine in metastatic squamous cell esophagual carcinoma. J Clin Oncol 1996;14:164-170.
18. Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn R: Chemotherapy of advanced esophageal carcinoma. Eastern Cooperative Oncology Group Experience. Cancer 1980;46:2149-2153.
19. Lokich J, Shea M, Chaffey J: Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 1987;60:275-279.
20. Alberts AS, Schoeman L, Burger W, Creef F, Falkson G: A phase II study of 5-fluorouracil and leucovorin in advanced carcinoma of the esophagus. Am J Clin Oncol 1992;15:35-36.
21. Kok TC, Van der Gaast A, Splinter TAW: 5-Fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Ann Oncol 1996;7:533-534.
22. Kelsen D, Lovett D, Wong J, Saltz L, Buckley M, Murray P, Heelan R, Lightdale C: Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 1992;10: 269-274.
23. Wadler S, Fell S, Haynes H, Katz HJ, Rozenblit A, Kaleya R, Wiernik PH: Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. Cancer 1993;71:1726-1730.
24. Kok TC, Van der Gaast A, Splinter TAW: 13-Cisretinoic acid and alpha-interferon in advanced squamous cell cancer of the esophagus. Eur J Cancer 1997;33:165-166.
25. Ilson DH, Kelsen DP: Chemotherapy in esophageal cancer. Anticancer Drugs 1993;4:287-299.
26. De Besi P, Toso S, Sileni VC, Bardini R, Castoro C, Salvagno L, Paccagnella A, Ruol A, Peracchia A, Fiorentino MV: Multimodality therapy for unresectable squamous cell carcinoma of the esophagus. Proc ASCO 1990;9:129.
27. Bleiberg H, Conroy T, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, DeBesi P, Gay F, Colette L, Sahmoud T: Randomised phase II study of cisplatin and 5-fluorouracil versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-1220.
28. Zaniboni A, Simuncini E, Tonini G, Pezzola D, Farfaglia R, Lancini GP, Marpicati P, Montini E, Marini G: Cisplatin, high-dose folinic acid and 5-fluorouracil in squamous cell carcinoma of the esophagus. A pilot study. Chemoterapia 1987;6: 387-389.
29. Feliu J, Gonzales Baron M, Garcia Giron C, Espinosa E, Vicent JM, Gomez Navarro J, Berrocal A, Ordonez A, Vilches Y, de Castro J, Diaz J: Phase II study of cisplatin. 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. Am J Clin Oncol 1996;19:577-580.
30. Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Kerezles R, Kelsen DP: A phase II trial of interferon alpha-2a, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer 1995;75:2197-2202.
31. Wadler S, Haynes H, Beitler JJ, Hu X, Fell S, Camacho M, Levine B, Wiernik PH: Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 1996;78:30-34.
32. Spiridonidis CH, Laufman LR, Jones JJ, Gray DJ, Cho CC, Young DC: A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer 1996; 77:2070-2077.
33. Kok TC, Van der Gaast A, Dees J, Eykenboom WMH, Van Overhagen H, Stoter G, Tilanus HW, Splinter TAW: Cisplatin and etoposide in oesophageal cancer: A phase II study. Br J Cancer 1996;74: 980-984.
34. Preusser P, Wilke H, Achterrath W, Pircher W, Meyer J, Blüm M, Lenaz L, Bünte H: Disease oriented phase II study with cisplatin, etoposide, and 5FU = PEF in advanced squamous cell carcinoma of the esophagus. Proc ASCO 1988;7:101.
35. Van der Gaast A, Kok TC, Splinter TAW: Phase II study of cisplatin, etoposide, 5-flourouracil and leucovorin in patients with adenocarcinoma of the esophagus. Proc ASCO 1997;16:306a.
36. Ilson DH, Ajani JA, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826-1834.
37. Garcia-Alfonso P, Guevara S, Lopez P, Martin JM, De Alvaro J, Lahoz C, Chaih C, Gonzalez C, Calvo FA, Perez-Manga G: Taxol and cisplatin + 5-fluorouracil sequential in advanced esophageal cancer. Proc ASCO 1998;17:260a.
38. Kok TC, Van der Gaast A, Kerkhots L, Splinter TAW: Biweekly administration of cisplatin and increasing doses of paclitaxel in patients with advanced esophageal cancer. Proc ASCO 1998;17:260a.
39. Darnton SJ, Allen SM, Edwards CW, Matthews HR: Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. J Clin Pathol 1993;46:51-55.
40. Kelsen D, Hilaris B, Coonley C, Chapman R, Lesser M, Dukeman M, Heelan R, Bains VI: Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma. Am J Med 1983;75:645-652.
41. Kies MS, Rosen ST, Tsang T, Shetty R, Schneider PA, Wallemark CB, Shields TW: Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. Cancer 1987;60:2156-2160.
42. Carey RW, Hilgenberg AD, Grillo HC, Mathisen DJ, Choi NC, Logan DL: Esophageal carcinoma: Long term follow-up of patients treated by neoadjuvant chemotherapy, surgery and possible post-operative radiation and/or chemotherapy. Proc ASCO 1990;9:105.
43. De Besi P, Toso S, Sileni VC, Bardini R, Castoro C, Salvagno A, Paccagnella A, Ruol A, Peracchia A, Fiorentino MV: Multimodality therapy for unresectable squamous cell carcinoma of the esophagus. Proc ASCO 1990;9:129.
44. Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C: Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer 1992;28A:880-884.
45. Huffman P, Vokes E, Ferguson M, Haraf D, Krishnasamy S, English C: Induction chemotherapy, surgery and concomitant chemo-radiotherapy for carcinoma of the esophagus. Proc ASCO 1992;11: 193.
46. Temeck BK, Liebmann JE, Theodossiou C, Steinberg SM, Cook JA, Metz DC, Shawker TH, Allegra CJ, Russo A, Pass HI: Phase II trial of 5-fluorouracil, leucovorin, interferon-α-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma. Cancer 1996;77:2432-2439.
47. Stahl M, Wilke H, Meyer HJ, Preusser P, Berns T, Fink U, Achterrath W, Knipp H, Harstrick A, Berger M, Schmoll HJ: 5-Fluorouracil, folinic acid, etoposide, and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the esophagus. Eur J Cancer 1994;30A:325-328.
48. Carey RW, Hilgenberg AD, Choi NC, Mathisen DJ, Grillo HC, Wain JC, Logan DL, Bromberg C: A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. Cancer 1991;68:489-492.
49. Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P: Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer 1995;31A:665-670.
50. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S: Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96:242-248.
51. Schlag PM: Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. Arch Surg 1992;127:1446-1450.
52. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, Mäntyla M, Modig H, Munck-Wikland E, Rosengren B, Tausjo J, Eigen K: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The Second Scandinavian Trial in esophageal cancer. World J Surg 1992;16:1104-1110.
53. Kok TC, von Lanschot J, Siersema PD, von Overhagen H, Tilanus HW: Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: Final report of a phase III multicenter randomized controlled trial. Proc ASCO 1997;16:277a.
54. Kelsen DP, Ginsberg R, Qian C, Gunderson L, Mortimer J, Estes N, Hailer D, Ajani J, Kocher W, Roth J, Minsky B: Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: A preliminary report of intergroup study 113 (RTOG 89-11). Proc ASCO 1997;16:276a.
55. Stahl M: What is the role of surgery in multimodality treatment of localized oesophageal cancer? Onkologie 1996;19:75-76.
56. Stahl M, Wilke H: Possibilities of non-resective treatment procedures in oesophageal cancer. Onkologie 1996;19:211-213.
57. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.